U.S. Capital Markets Stock News

NYSE:GRDN
NYSE:GRDNHealthcare

Is Guardian Pharmacy (GRDN) Using Tech-Driven Kentucky Expansion to Redefine Its Long-Term Care Edge?

Guardian Pharmacy Services, Inc. has opened its first physical long-term care pharmacy in Lexington, Kentucky, operating as Guardian Pharmacy of Kentucky, expanding its support for assisted living, skilled nursing, behavioral health, and intellectual and developmental disability communities with advanced technology and automation. This move deepens Guardian’s presence in Kentucky while showcasing its focus on technology-enabled pharmacy operations to better serve complex long-term care needs...
NYSE:DMC
NYSE:DMCFood

Del Monte (DMC) Stock May Be Fully Priced On Cash Flow Yet A Bargain On Earnings

Del Monte stock has delivered a 19.6% gain over the past three years, yet the latest valuation work sends mixed messages, with the Discounted Cash Flow (DCF) estimate pointing to a premium to intrinsic value while earnings based multiples look more forgiving. Over the past three years Del Monte has returned 19.6%, which is a solid result but not enough on its own to show whether the current share price leaves much safety margin. The key swing factors for Del Monte's valuation are how...
NasdaqGS:FLEX
NasdaqGS:FLEXElectronic

AI Infrastructure Stocks With Real Backlog Strength Beyond The Usual Data Center Names

Global purchasing manager data now points to broad expansion across key European economies, with services activity picking up and manufacturing showing pockets of improvement. That kind of real world demand often requires more data, more compute, and more power. For investors, this puts AI infrastructure stocks in the spotlight. This article highlights three screeners that stand out as potential beneficiaries of that build out story. The three AI infrastructure stocks covered below are only a...
NasdaqGS:PYPL
NasdaqGS:PYPLDiversified Financial

PayPal (PYPL) Stock Looks Reasonable On Earnings But Weak On Returns

PayPal Holdings has been through a tough stretch, with the stock down about 78.9% over the past five years, yet its current valuation checks still lean toward the shares looking cheap on several measures. After a recent rally and fresh attention following company updates, investors are weighing whether that apparent discount is justified by the underlying business and its prospects. The roughly 78.9% decline over five years means long term holders have absorbed heavy losses, which often...
NasdaqGS:ZM
NasdaqGS:ZMSoftware

Zoom (ZM) Stock Looks Undervalued With Cash Flow And Earnings In Focus

Zoom Communications stock has bounced back in the shorter term, yet the valuation work still points to some potential upside, with both the Discounted Cash Flow (DCF) intrinsic value estimate and market multiples indicating the shares screen as undervalued. Over the past 5 years, Zoom Communications shareholders have seen the stock fall about 71.9%, which still dominates the long term picture even after the more recent recovery. The company’s ability to keep converting its collaboration...
NasdaqGM:VERX
NasdaqGM:VERXSoftware

Has Vertex (VERX) Fallen Far Enough To Look Undervalued?

Vertex stock has had a rough run over the past year, yet the current valuation checks still lean on the cheap side. After a steep share price decline, investors are now weighing whether today's lower level reflects a genuine opportunity or ongoing concern. Over the past 12 months, Vertex has declined 56.5%, which puts recent valuation signals under a harsher spotlight for anyone considering the stock today. Recent hires focused on AI driven product and technology roles may support...
NYSE:AMT
NYSE:AMTSpecialized REITs

American Tower (AMT) Earnings Lift Puts Its Valuation Back In Focus

American Tower (AMT) drew investor attention after reporting second quarter 2026 results with higher revenue, net income and earnings per share, alongside updated full year guidance and a completed multi year share repurchase program. See our latest analysis for American Tower. Despite the stronger second quarter earnings and updated 2026 outlook, American Tower’s recent share price performance has been mixed, with the stock down 6.5% over three months and the 1 year total shareholder return...
NasdaqGS:SIRI
NasdaqGS:SIRIMedia

Sirius XM (SIRI) Stock May Be 32% Below Fair Value

Sirius XM Holdings stock has delivered a strong 53.6% return over the past year, while both an intrinsic value estimate using a Discounted Cash Flow (DCF) approach and traditional earnings multiples currently point to the shares trading below their estimated value. Over the last 1 year Sirius XM Holdings has returned 53.6%, which puts extra focus on whether the current price still offers a margin between market value and fundamentals. The company’s subscription based model can support steady...
NYSE:BLK
NYSE:BLKCapital Markets

BlackRock (BLK) Launches Tokenized Funds, Is The Platform Story Already Priced In?

BlackRock (BLK) has put tokenized cash management in focus with the launch of two blockchain-based money market vehicles, BSTBL and BRSRV, that aim to pair regulated fund structures with digital asset infrastructure. See our latest analysis for BlackRock. Against this backdrop of tokenized funds and digital infrastructure partnerships, BlackRock’s momentum has picked up, with a 12.10% 1 month share price return, a 6.17% 3 month share price return and a 3.28% 1 year total shareholder return...
NYSE:TNK
NYSE:TNKOil and Gas

Earnings Jump And Dividend Hike Could Be A Game Changer For Teekay Tankers (TNK)

Teekay Tankers Ltd. reported its second-quarter 2026 results, with revenue rising to US$379.51 million and net income to US$225.91 million, alongside a fixed quarterly cash dividend of US$0.25 per share payable on August 21, 2026. Beyond the headline earnings jump, Teekay Tankers’ higher per-share profitability and continued cash returns underline how its current operations are converting into shareholder-focused payouts. Next, we’ll examine how this earnings strength and ongoing dividend...
NYSE:JBL
NYSE:JBLElectronic

Jabil Stock And 2 More US Import Dependent Companies Tied To Tariff Refunds

After the Supreme Court ordered roughly US$100 billion in tariff refunds to import heavy corporations and curbed the president’s power to impose duties under emergency rules, trade policy suddenly feels less predictable and more interesting for investors. Some stocks now sit closer to the flow of refunded cash and shifting tariff tools than others. This article walks through three US large cap import dependent stocks that are closely tied to this story. The three stocks that follow are only a...
NYSE:CDE
NYSE:CDEMetals and Mining

Why Coeur Mining (CDE) Is Up 19.1% After Record Q2 Output And Cautious 2026 Guidance

Coeur Mining, Inc. reported very large year-over-year and quarter-over-quarter increases in second-quarter 2026 revenue and net income, driven by record gold production of 163,490 ounces, steady silver output of 4.4 million ounces, and 11.4 million pounds of copper, while also updating full-year and nine-month 2026 production guidance across all three metals. An interesting nuance is that, despite record quarterly gold production and much higher sales and earnings, Coeur trimmed its...
NasdaqGS:SHOP
NasdaqGS:SHOPIT

US Stock Market Today: S&P 500 Futures Edge Higher On Easing Yield Pressures

The Morning Bull - US Market Morning Update Thursday, Aug, 6 2026 US stock futures are pointing higher this morning, with E-mini S&P 500 contracts up about 0.2%, as investors weigh cooling inflation signals abroad against shifting interest rate expectations. A key driver is the drop in the US 10 year Treasury yield to around 4.6% on signs of a possible Hormuz deal and softer oil prices, which eases pressure on fuel costs and raises questions about how aggressive future rate hikes might be. At...
NasdaqGM:LMAT
NasdaqGM:LMATMedical Equipment

LeMaitre Vascular (LMAT) Stock Price Hit By Revenue Guidance Cut

LeMaitre Vascular entered this earnings season with a reputation for steady, high margin growth. The stock now tells a very different story. Shares closed yesterday at US$105.78 and then reset sharply lower to about US$79, a one day drop of more than 25% as investors reacted to Q2 numbers and guidance. The headline is not weak profitability. Q2 gross margin reached 72.1% and operating margin came in at 29%, both high for medical devices. The pressure point is a trim to full year revenue...
NasdaqGS:WWD
NasdaqGS:WWDAerospace & Defense

Woodward (WWD) Posted Strong Q3 Growth, Is The Stock Still A Bargain?

Why Woodward Stock Is Back In Focus After Q3 Results Woodward (WWD) is drawing fresh attention after reporting third quarter and year to date results on July 29, 2026, with higher sales and net income than the same periods a year earlier. See our latest analysis for Woodward. Despite the strong Q3 update and ongoing share buybacks completed in June 2026, Woodward’s recent share price has cooled, with a 30 day share price return of down 11.85%. However, its 1 year total shareholder return of...
NasdaqGM:MDB
NasdaqGM:MDBIT

3 Enterprise AI Stocks Worth Watching As Cloud Spending Rises

Google Cloud’s 82% Q2 revenue growth sits alongside leadership changes and rising capital spending, which together have pushed Alphabet’s share price under closer scrutiny. That mix of strong cloud and enterprise AI demand, combined with fresh questions about talent and investment priorities, is creating both excitement and anxiety. This article spotlights 3 stocks exposed to that same news backdrop, helping you judge where the current AI and cloud momentum might matter most. The stocks...
NYSE:APD
NYSE:APDChemicals

How Investors Are Reacting To Air Products (APD) Turning Higher Sales Into a Surprise Quarterly Loss

In the past quarter, Air Products and Chemicals, Inc. reported third-quarter 2026 sales of US$3,161 million, up from US$3,022.7 million a year earlier, but swung from net income of US$713.8 million to a net loss of US$1,440.8 million, with basic and diluted loss per share of US$6.47 from continuing operations. Over the first nine months of 2026, sales increased to US$9,435.3 million from US$8,870.4 million, yet the company moved from net income of US$399.4 million to a net loss of US$52.2...
NasdaqGM:NTLA
NasdaqGM:NTLABiotechs

Intellia Therapeutics (NTLA) Stock Looks Overvalued On Sales But Fairer On Broader Checks

Intellia Therapeutics stock is coming off a very heavy five year decline, yet the current valuation checks still suggest a mixed picture rather than a clear bargain. Over the past five years, Intellia Therapeutics has delivered a share price decline of about 93%, which means long term holders have seen most of their capital eroded. Future value for shareholders may hinge on whether Intellia Therapeutics can turn its R&D pipeline into commercially viable therapies while managing the risks...
NYSE:PRIM
NYSE:PRIMConstruction

Primoris (PRIM) Stock Sinks As Renewables Missteps Crush Margins

Primoris Services came into this earnings release riding a mixed tape, with the stock up over the past week but down about 23% over the past three months. The immediate verdict was harsh. Shares dropped roughly 8% to about US$83 after a quarter that flipped from profit to loss, with basic earnings per share at a loss of US$0.45 on revenue of about US$1.7b. For a construction and infrastructure contractor that many investors view as a steady compounder, that kind of margin and profit squeeze...
NasdaqGS:AGYS
NasdaqGS:AGYSSoftware

Agilysys (AGYS) Could Be 17% Undervalued Following Earnings And Higher Guidance

Agilysys earnings and guidance update Agilysys (AGYS) reported first quarter 2026 results on July 27, with revenue of $87.68 million and net income of $8.99 million. The company also raised its fiscal 2027 earnings and revenue guidance. See our latest analysis for Agilysys. Agilysys shares trade at $110.74, with the stock easing over the past week and month, yet showing a 90 day share price return of 51.84% and a 5 year total shareholder return of 93.20%, which points to momentum building...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics (TGTX) Looks Fairly Valued After Raised 2026 Guidance And Mixed Q2 Earnings

TG Therapeutics (TGTX) is back in focus after its Q2 2026 earnings update, which combined higher revenue and raised full year guidance with lower net income and earnings per share. See our latest analysis for TG Therapeutics. The raised 2026 guidance and focus on BRIUMVI come after a sharp short term pullback, with a 7 day share price return of down 6.7% and 30 day share price return of down 10.1%. TG Therapeutics still shows strong momentum over longer periods, with a year to date share...
NYSE:MWA
NYSE:MWAMachinery

Does Strong Q3 Results And Steady Dividend Policy Change The Bull Case For Mueller Water Products (MWA)?

Mueller Water Products, Inc. has reported its third‑quarter 2026 results, with sales of US$395.9 million and net income of US$67.3 million, alongside affirming a quarterly dividend of US$0.07 per share payable on August 20, 2026. The company’s 2025 Sustainability Report underscores record safety performance, lower greenhouse gas emissions, and meaningful water loss savings from its leak detection technologies, highlighting how operational and environmental initiatives are supporting its...
NasdaqGS:WDC
NasdaqGS:WDCTech

Western Digital (WDC) Stock Could Be 49% Undervalued After Weak Guidance

Western Digital stock has had a very strong three year run, yet current valuation checks still suggest the market price sits well below an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and on earnings multiples. With such a sharp past return and a valuation screen that points to the shares looking undervalued, investors are weighing how much of that gap is justified by the risks now in focus. Western Digital has delivered a very large return over the last three...
NYSE:PEB
NYSE:PEBHotel and Resort REITs

Pebblebrook Hotel Trust (PEB) Could Be 4% Overvalued Following Raised 2026 Guidance

Pebblebrook Hotel Trust (PEB) has drawn fresh attention after reporting its second quarter 2026 results, highlighting higher net income and improved earnings per share, along with raised full year earnings guidance and ongoing share repurchases. See our latest analysis for Pebblebrook Hotel Trust. Pebblebrook Hotel Trust's share price is US$19.09, with a 30 day share price return of 2.36% and a 90 day share price return of 31.47%. The 1 year total shareholder return of 94.01% contrasts with a...